Overview

Use of Pan-Vascular Endothelial Growth Factor Receptor (Pan-VEGF) Blockade for the Treatment of Retinopathy of Prematurity (ROP) (Compassionate Use BLOCK-ROP)

Status:
Temporarily not available

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to provide access to intravitreal injection of Avastin in high-risk infants who do not otherwise qualify for study NCT00702819, an investigational multi-site study examining Avastin use for retinopathy of prematurity.

Details

Lead Sponsor:

Children's Hospital Los Angeles

Treatments:

Bevacizumab
Endothelial Growth Factors
Mitogens